Table 4.
Most Frequently Reported TEAEs (Safety Population) a
| Preferred Term, n (%) | Placebo, n = 59 | Solriamfetol 300 mg, n = 56 | Solriamfetol 900 mg, n = 60 | Moxifloxacin 400 mg, n = 58 | Total, N = 60 |
|---|---|---|---|---|---|
| Any adverse event | 7 (12) | 16 (29) | 42 (70) | 11 (19) | 46 (77) |
| Nausea | 0 (0) | 4 (7) | 20 (33) | 6 (10) | 26 (43) |
| Dizziness | 1 (2) | 4 (7) | 18 (30) | 4 (7) | 20 (33) |
| Headache | 2 (3) | 4 (7) | 14 (23) | 4 (7) | 17 (28) |
| Palpitations | 0 (0) | 3 (5) | 17 (28) | 0 (0) | 19 (32) |
| Anxiety | 0 (0) | 2 (4) | 12 (20) | 1 (2) | 14 (23) |
| Insomnia | 0 (0) | 2 (4) | 8 (13) | 2 (3) | 12 (20) |
| Asthenia | 0 (0) | 2 (4) | 7 (12) | 1 (2) | 9 (15) |
| Chest discomfort | 0 (0) | 2 (4) | 7 (12) | 1 (2) | 8 (13) |
| Paresthesia | 0 (0) | 1 (2) | 12 (20) | 0 (0) | 13 (22) |
| Nervousness | 0 (0) | 1 (2) | 9 (15) | 0 (0) | 10 (17) |
| Dizziness, postural | 0 (0) | 0 (0) | 13 (22) | 2 (3) | 13 (22) |
| Dry mouth | 0 (0) | 0 (0) | 12 (20) | 1 (2) | 12 (20) |
| Vomiting | 0 (0) | 0 (0) | 8 (13) | 0 (0) | 8 (13) |
| Dyspnea | 0 (0) | 0 (0) | 7 (12) | 1 (2) | 8 (13) |
| Tremor | 0 (0) | 0 (0) | 6 (10) | 2 (3) | 8 (13) |
| Feeling hot | 0 (0) | 0 (0) | 6 (10) | 0 (0) | 6 (10) |
TEAEs, treatment‐emergent adverse events.
a
Events occurring in ≥10% of participants.